GSK to buy US cancer drug developer amid pressure from activist investor - The Guardian

GlaxoSmithKline’s £1.5bn Sierra Oncology deal comes after pressure from Elliott to boost its pipeline

The UK drug company GlaxoSmithKline has agreed a £1.5bn deal to buy a US cancer treatment developer, Sierra Oncology, as it tries to fend off pressure from the activist shareholder Elliott Management… [+2372 chars]

full article...